# The Misuse of Drugs (Designation) (Amendment) (England, Wales and Scotland) Order 2013 (revoked)

        - Previous
        - Next

U.K.

Statutory Instruments

# 2013 No. 177

Dangerous Drugs, England And Wales

Dangerous Drugs, Scotland

# The Misuse of Drugs (Designation) (Amendment) (England, Wales and Scotland) Order 2013

Made

31st January 2013

Laid before Parliament

4th February 2013

Coming into force

26th February 2013

The Secretary of State, in exercise of the powers conferred by section 7(4) of the Misuse of Drugs Act 1971 F1 and after consultation with the Advisory Council on the Misuse of Drugs in accordance with section 7(7) of that Act, makes                           the following Order:                        

F11971 c. 38.

## Citation, commencement and extentU.K.

1.—(1) This Order may be cited as the Misuse of Drugs (Designation) (Amendment) (England, Wales and Scotland) Order 2013 and shall                     come into force on 26th February 2013.                  

(2) This Order extends to England and Wales and Scotland.

## Amendments to the Misuse of Drugs (Designation) Order 2001U.K.

2.  Part 1 of the Schedule to the Misuse of Drugs (Designation) Order 2001 F2 (which specifies controlled drugs to which section 7(4) of the Misuse of Drugs Act 1971 applies) shall be amended as follows.                  

F2S.I. 2001/3997 as amended by S.I. 2005/1652, **S.I**. 2009/3135, S.I. 2010/1143, **S.I**. 2010/1800, S.I. 2011/447, **S.I**. 2012/276 which was not published and was revoked by S.I. 2012/384, and S.I. 2012/1310.

## 

3.  In paragraph 1(a) after “*N,N*-Diethyltryptamine”, insert—                  

“2-((Dimethylamino)methyl)-1-(3-hydroxyphenyl)cyclohexanol”.                  

## 

4.  For paragraph 1(l), (m), (n) and (o) F3, substitute—                  

“(l)Any compound structurally derived from 3–(1–naphthoyl)indole, 3-(2-naphthoyl)indole, 1*H*–indol–3–yl–(1–naphthyl)methane or 1*H*-indol-3-yl-(2-naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl,                           hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (*N*-methylpiperidin-2-yl)methyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent                           and whether or not substituted in the naphthyl ring to any extent.                  

(m)Any compound structurally derived from 3–(1–naphthoyl)pyrrole or 3-(2-naphthoyl)pyrrole by substitution at the nitrogen atom                           of the pyrrole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (*N*-methylpiperidin-2-yl)methyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the pyrrole ring to any extent                           and whether or not substituted in the naphthyl ring to any extent.                  

(n)Any compound structurally derived from 1–(1–naphthylmethylene)indene or 1-(2-naphthylmethylene)indene by substitution at the                           3–position of the indene ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (*N*-methylpiperidin-2-yl)methyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indene ring to any extent                           and whether or not substituted in the naphthyl ring to any extent.                  

(o)Any compound structurally derived from 3–phenylacetylindole by substitution at the nitrogen atom of the indole ring by alkyl,                           haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (*N*-methylpiperidin-2-yl)methyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent                           and whether or not substituted in the phenyl ring to any extent.”.                  

F3Paragraph 1(l), (m), (n) and (o) was inserted by article 2(c) of S.I. 2009/3135.

## 

5.  After paragraph 1(p) F4 insert—                  

“(pa)Any compound structurally derived from 3-benzoylindole by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl,                           alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (*N*-methylpiperidin-2-yl)methyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent                           and whether or not substituted in the phenyl ring to any extent.                  

(pb)Any compound structurally derived from 3-(1-adamantoyl)indole or 3-(2-adamantoyl)indole by substitution at the nitrogen atom                           of the indole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (*N*-methylpiperidin-2-yl)methyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent                           and whether or not substituted in the adamantyl ring to any extent.                  

(pc)Any compound structurally derived from 3-(2,2,3,3-tetramethylcyclopropylcarbonyl)indole by substitution at the nitrogen atom                           of the indole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (*N*-methylpiperidin-2-yl)methyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent.”.                  

F4Paragraph 1(p) was inserted by article 2(c) of S.I. 2009/3135.

## 

6.  After paragraph 1(s) F5, insert—                  

“(t)1-Phenylcyclohexylamine or any compound (not being eticyclidine, ketamine, phencyclidine, rolicyclidine, tenocyclidine or                           tiletamine) structurally derived from 1-phenylcyclohexylamine or 2-amino-2-phenylcyclohexanone by modification in any of the                           following ways, that is to say,                  

(i)by substitution at the nitrogen atom to any extent by alkyl, alkenyl or hydroxyalkyl groups, or replacement of the amino group                           with a 1-piperidyl, 1-pyrrolidyl or 1-azepyl group, whether or not the nitrogen containing ring is further substituted by                           one or more alkyl groups;                  

(ii)by substitution in the phenyl ring to any extent by amino, alkyl, hydroxy, alkoxy or halide substituents, whether or not further                           substituted in the phenyl ring to any extent;                  

(iii)by substitution in the cyclohexyl or cyclohexanone ring by one or more alkyl substituents;                  

(iv)by replacement of the phenyl ring with a thienyl ring.”.                  

F5Paragraph 1(s) was inserted by article 2 of S.I. 2012/1310.

## 

7.  For paragraph 3, substitute—                  

### 

“3.Any ester or ether of a substance specified in paragraph 1 (not being 2-((dimethylamino)methyl)-1-(3-hydroxyphenyl)cyclohexanol)                        or paragraph 2.”.                  

Jeremy Browne

 Minister of State

 Home Office

31st January 2013

## Explanatory Note

(This note is not part of the Order)

Section 7(3) of the Misuse of Drugs Act 1971 requires regulations to be made to allow the use for medical purposes of the                        drugs which are subject to control under that Act. Section 7(3) does not apply to any drug designated by order under section                        7(4) as a drug to which section 7(4) is to apply. This Order amends the Misuse of Drugs (Designation) Order 2001 by inserting                        into Part 1 of the Schedule to that Order 2-((dimethylamino)methyl)-1-(3-hydroxyphenyl)cyclohexanol, commonly known as *O*-desmethyltramadol; new categories of synthetic cannabinoids; and 2-(ethylamino)-2-(3-methoxyphenyl)cyclohexanone, commonly                        known as methoxetamine, and other compounds related to ketamine and phencyclidine. Article 7 substitutes a new paragraph 3                        to the effect that an ester or ether of *O*-desmethyltramadol is not designated as a drug to which section 7(4) of the Misuse of Drugs Act 1971 applies.